RARE
Ultragenyx Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.73
+5.93%Sep 2, 2026, 20:19 UTC
Ultragenyx Pharmaceutical announced on Wednesday that its experimental drug for a rare genetic neurodevelopmental disorder failed to meet the primary endpoint in a late-stage trial, causing its shares to plunge 40% in aftermarket trading.
Aug 19, 2026, 21:21 UTC
The U.S. FDA approved Ultragenyx's GENGLYCOS gene therapy, the first-ever treatment for the underlying cause of glycogen storage disease type Ia.
Aug 13, 2026, 07:31 UTC
Assenagon Asset Management S.A. sold 2,136,807 shares of Ultragenyx Pharmaceutical Inc., reducing its stake by 94.6% during the quarter, as disclosed in a 13F filing.
Source:Aug 4, 2026, 20:05 UTC
Ultragenyx Pharmaceutical reported its financial results for the second quarter of 2026, with total revenue of $214 million, including Crysvita revenue of $156 million and Dojolvi revenue of $27 million, and reaffirmed its 2026 financial guidance.
Jul 27, 2026, 12:00 UTC
RA Capital and other investors are investing $175 million in Oak Hill Bio to revive an experimental Angelman syndrome drug shelved by Roche.
Source: